B
Bull
Bull · 25%LNTH
$109.31
Scenario price
$100.320
+0.221 (+0.22%)At close
Loading chart…
- High
- 100.500
- Open
- 100.490
- VWAP
- 100.33
- Volume
- 771.66K
- Mkt Cap
- 5.64B
- Low
- 100.170
- Amount
- 77.42M
- EV/EBITDA, TTM
- 12.74
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
AI analysis of Lantheus Holdings Inc (LNTH)
HoldLantheus Holdings Inc is currently trading at $99.80, which is below the analyst price target of $102.50, indicating a potential upside of about 2.5%. However, the RSI is at 38.57, suggesting that the stock is approaching oversold territory, which could indicate a potential rebound. The recent FDA approval of Bravnetsa is a positive catalyst, but the acquisition by Curium for $102.50 per share raises concerns about the stock's future performance as it may no longer trade on fundamentals. The main risk is the hedge fund selling activity, which increased by 2127.26% over the last quarter, indicating a lack of confidence among institutional investors. Therefore, while there are some positive indicators, the significant insider selling and the downgrade of analyst ratings suggest that it may be prudent to hold rather than buy at this time.
Analyst Ratings (4)
-18.09% Downside
Buy
3 Buy
1 Hold
0 Sell
Current: 100.32
Low
70.00
Average
82.17
High
105.00
CJS Securities
Market Perform
$102.50
2026-08-04
CJS Securities
2026-08-04
Price Target
$102.50
Market Perform
Truist
Hold
$125
2026-08-03
Truist
2026-08-03
Price Target
$125
Hold
Leerink
Market Perform
$102.50
2026-08-03
Leerink
2026-08-03
Price Target
$102.50
Market Perform
TD Cowen
Hold
$110
2026-08-03
TD Cowen
2026-08-03
Price Target
$110
Hold
William Blair
Market Perform
$5.00
2026-08-03
William Blair
2026-08-03
Price Target
$5.00
Market Perform
Valuation Metrics
The current forward P/E ratio for Lantheus Holdings Inc (LNTH) is 14.29, compared to its 5-year average forward P/E of 14.51.
Alphio AI Price Scenarios for LNTH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding LNTH
Events Timeline
News
7.009-29PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
9.009-22NASDAQ.COMLantheus Secures FDA Approval for Bravnetsa Radiopharmaceutical
7.009-11PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
7.008-07PRnewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
9.008-03stocktwitsFDA Approval Updates for Biotech Companies
LNTH FAQ — answered by Alphio AI
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).
Lantheus Holdings Inc is currently trading at $99.80, which is below the analyst price target of $102.50, indicating a potential upside of about 2.5%. However, the RSI is at 38.57, suggesting that the stock is approaching oversold territory, which could indicate a potential rebound. The recent FDA approval of Bravnetsa is a positive catalyst, but the acquisition by Curium for $102.50 per share raises concerns about the stock's future performance as it may no longer trade on fundamentals. The main risk is the hedge fund selling activity, which increased by 2127.26% over the last quarter, indicating a lack of confidence among institutional investors. Therefore, while there are some positive indicators, the significant insider selling and the downgrade of analyst ratings suggest that it may be prudent to hold rather than buy at this time.
4 analysts cover LNTH: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 82.17.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.